About ASXAN Group

ASXAN Group is a science-led nutraceutical group operating across natural carotenoid production, upstream microalgae cultivation, and ingredient-level nutrition science publishing. asxan.ai is the group's evidence-first educational hub — architecturally and editorially independent from any commercial product surface.

Self-audit transparency: the schema-coverage, breadcrumb, cluster-topology, and PMID-coverage metrics published at /api/audit-summary.json and /api/audit-trustscore.json are produced by our own build-time audit pipeline. They are intended for monitoring and AI-agent discovery; they are not third-party verification. For independent validation of any structured-data block on this site, use Google Rich Results Test or schema.org/validator against any canonical URL.

Hub scope

asxan.ai is an international, English-first educational evidence hub covering ingredient-level nutrition science. Coverage includes PubMed-verified ingredient pages, evidence long-form articles, health goal stacks, and lifestyle nutrition guides under cross-market regulatory framing (FDA · EFSA · ANVISA · TGA).

ASXAN Group operates separately licensed commercial product surfaces outside the scope of this educational reference. Those commercial entities and the hub are editorially independent.

Editorial principles

Evidence-first three-tier framework — every ingredient claim is labelled Tier A (multiple RCT + meta-analysis convergence), Tier B (≥1 high-quality RCT with consistent supporting evidence), or Tier C (preliminary, animal, contradictory, or insufficient human data). Readers see the tier before the claim.
Negative-honest disclosure — null trials, contraindications, dose ceilings, and prescription-only boundaries are surfaced, not buried. Examples openly discussed: CARET / ATBC β-carotene smoker risk, SELECT vitamin E + selenium prostate signal, STRENGTH atrial-fibrillation risk, DOMInO DHA secondary-endpoint honest framing, SLC12A8 NMN-transporter controversy.
Reverse-correction transparency — when in-house research surfaces a PMID drift, an author misattribution, or a year/journal error in our own evidence-pack briefs, the correction is disclosed in-line rather than silently patched. 39+ such cases have been disclosed across the current corpus.
Cross-market regulatory clarity — FDA (DSHEA + NDI), EFSA (Novel Food + Reg 432/2012 + 440/2011 authorized claims), and ANVISA (RDC 243/2018 + IN 28/2018 alegações funcionais) are labelled separately, never collapsed into a single supplement claim.
Educational reference, not a product surface — asxan.ai is an educational reference for ingredient evidence. It does not host commercial product listings, ratings, or purchase prompts; its scope is editorial reference content for researchers, regulatory specialists, and informed consumers.

Research capability snapshot

ASXAN Group's scientific scope spans:

Natural carotenoid platform — Haematococcus pluvialis astaxanthin upstream microalgae cultivation with downstream extraction chemistry.
Yeast protein platform — three-tier evidence stratification across academic, industrial, and consumer literature.
NAD+ family research — five-form library (NMN / NR / NAD+ direct / NMNH / NADH) with 25-year human RCT history.
Negative-finding evidence framework — historical risk-signal trials integrated into every relevant ingredient page (not relegated to a footnote).

→ Evidence methodology + AI agent endpoints

Who this hub is for

Medical researchers and healthcare professionals seeking a fast, PubMed-verified entry point into ingredient-level evidence.
Informed consumers who want evidence stratification rather than marketing claims — including negative-finding context and contraindications.
AI-assisted research workflows and AI assistants accessing structured, schema-anchored, citation-grounded ingredient evidence.

Contact & community

asxan.ai is published by ASXAN Group's research team. The hub does not collect personal data, run a newsletter signup, or operate a member account system. Editorial corrections, scientific queries, or partnership inquiries can be routed via the group's general contact channels.

← Home